CPT code 55881 defines the use of a transurethral ultrasound transducer previously inserted in the urethra to perform transurethral ultrasound ablation (TULSA) of prostate tissue under magnetic resonance imaging (MRI) guidance. This technologically advanced, image-guided ablative procedure is important nationally as an option for focal or whole-gland prostate tissue ablation that leverages MRI for real-time targeting and monitoring.

Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and reimbursement for MRI-guided TULSA vary across commercial carriers and Medicare policy. Readers will find clinical context for the procedure, payer coverage patterns, common billing modifiers, and benchmarking where available. The publication outlines the service setting expectations, typical clinical indications, and coding considerations tied to device- and image-guided prostate ablation.

This summary equips clinicians, billing professionals, and policy analysts with a concise reference to the procedure represented by CPT code 55881, the typical sites of service, the major payers addressed in the analysis, and the scope of topics covered including policy implications and coding practice notes. Data not available in the input will be identified where applicable.